Trial
NCT06050954
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Fox Chase Cancer Center
Collaborators
—
Condition
Metastatic Urothelial Carcinoma
Intervention
Pembrolizumab (200mg)
Why stopped
Change in standard of care.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-09